Decoy Therapeutics Corrects Warrant Inducement Announcement
Boston, Massachusetts, U.S., September 22, 2026 Decoy Therapeutics, Inc., a clinical-stage biotechnology company developing antiviral therapeutics, has issued a...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Boston, Massachusetts, U.S., September 22, 2026 Decoy Therapeutics, Inc., a clinical-stage biotechnology company developing antiviral therapeutics, has issued a...
New Taipei City, Taiwan, September 22, 2026 Caliway Biopharmaceuticals has announced positive final results from its randomized, single-blind, placebo-controlled...
North Chicago, Illinois, and San Diego, California, U.S., September 21, 2026 AbbVie and Iambic have announced a multi-year collaboration...
Beerse, Belgium, September 21, 2026 Johnson & Johnson has reached a major European regulatory milestone with the European Commission’s...
Pleasanton, California, U.S., September 21, 2026 Veeva Systems has introduced Veeva Falcon Router, an agentic artificial intelligence solution designed...
Germantown, Maryland, U.S., September 21, 2026 Precigen has announced that the U.S. Food and Drug Administration (FDA) has granted...
Marina del Rey, California, U.S., September 21, 2026 Armata Pharmaceuticals announced that new data evaluating AP-SA02, its investigational bacteriophage...
Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...
New York, United States, September 20, 2026 IntraBio Inc. has announced that the U.S. Food and Drug Administration (FDA)...
Washington, D.C., September 20, 2026 The Heart Failure Society of America (HFSA) has announced the late-breaking clinical research program...
